Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Gurupup who wrote (4557)	9/8/1998 4:17:00 PM
From: Bradpalm1	Respond to of 5736

SOURCE: EQUITIES Magazine LLC 'J'Accuse...' Barron's and Short Seller Manuel Asensio Have Smeared an Innocent Man NEW YORK, Sept. 8 /PRNewswire/ -- In EQUITIES combined July/August 1998 issue, Editor Robert J. Flaherty charges Barron's July articles ''Wounded Lion'' and ''L'Affaire Dreyfus,'' like the original French generals who victimized a defenseless Jew, have blamed an innocent man. He is underwriter Peter Janssen, and he was blamed for the poor performance of two Dreyfus funds. Yet during the period in which Barron's graphed the collapse of the two Dreyfus funds, the three Janssen/Meyers-backed medical stocks rose. The stock performance helped -- not hurt -- Dreyfus Funds' performance, exactly opposite to what Barron's published. Unreported by Barron's was significant prepublication trading by Avalon Research of Boca Raton, Fla. Also overlooked was that Nasdaq reports that two of the three stocks, Chromatics Color Sciences (Nasdaq: CCSI - news) and the warrant and common stock of Cytoclonal Pharmaceutical (Nasdaq: CYPII - news) were being still currently depressed by short sellers who were failing to deliver borrowed shares on time, according to Nasdaq statistics. ''This is naked short selling,'' Flaherty said. The third stock, MacroChem (Nasdaq: MCHM - news), is also under attack by short sellers According to Flaherty, Barron's relied heavily on fraud and other charges broadcast over the Internet by short-seller Manuel Asensio of Asensio & Co. He has charged about 21 companies with fraud. Barron's failed to report that Asensio himself has been accused of fraud in a still-ongoing law suit for his own activities on the day the stock market fell over 22.6% in the October 1987 crash. Editor Flaherty labeled EQUITIES' investigation ''one of the most important stories of my 37-years in financial journalism'' because the entire career of one individual could be damaged by this smear. ''Janssen had made a brilliant start in applying the principles of positive thinking to business when the short sellers struck and blackened his image,'' Flaherty said. Also in this issue EQUITIES spotlights America's fastest growing companies with five-year annual average earnings growth of 20% or better, a benchmark EQUITIES used to select managements with a superior long-term performance. EQUITIES is an award-winning, 47-year-old monthly magazine that covers promising, quality middle-market and emerging public companies and their environment. A twelve-month subscription is $36. SOURCE: EQUITIES Magazine LLC

To: Gurupup who wrote (4557)	9/9/1998 10:49:00 AM
From: JanyBlueEyes	Read Replies (4) \| Respond to of 5736

Pediatrics 1998 Sep;102(3):E28 Noninvasive estimation of serum bilirubin. Tayaba R, Gribetz D, Gribetz I, Holzman IR Department of Pediatrics, City Hospital Center at Elmhurst, Queens, New York. [Medline record in process] Objective. The aim of this study was to evaluate the accuracy and clinical usefulness of a new computer-driven, hand-held device (Chromatics Colormate III) to estimate serum bilirubin from skin-reflectance (skin color) of neonates. Study Design. A total of 2441 infants (both term and premature) at two hospitals had repeated measurements of transcutaneous bilirubin. Of these infants, 900 had one or more laboratory determinations of serum bilirubin. Many of the infants had early measurements of skin color before the onset of jaundice. A visual estimate of the degree of jaundice was made by a health care worker when the laboratory study was drawn. A subgroup of 61 infants was also studied while undergoing phototherapy with a total of 284 comparisons obtained. The reproducibility of the instrument was assessed separately using standardized color tiles and repeated measurements by multiple operators. Results. The range of serum bilirubin measurements that had concurrent skin color measurements was 3.22 to 338.1 &mgr;mol/L (0.2 to 21 mg/dL). The linear regression indicated an r = 0.956, and 95% of the skin color measurements were within 32.2 &mgr;mol/L (2.0 mg/dL). There was no interference with the accuracy of the device because of infant race or weight, or because of the use of phototherapy. The device provided reproducible information when infants were tested repeatedly over 30 minutes; the coefficient of variation for the transcutaneous bilirubin measurement was 3.1% around a mean estimate of 135.32 &mgr;mol/L (8.4 mg/dL). Conclusion. The Chromatic Colormate III allows for a clinically useful estimate of serum bilirubin in a wide variety of infants. By using a color discrimination algorithm and obtaining a skin measurement before the onset of icterus, this instrument can provide valuable clinical information that obviates the need for serum bilirubin determinations. Its use in newborn nurseries may allow physicians to shorten length of stay more safely and decrease the use of invasive blood tests. PMID: 9724676, UI: 98393764